BioPorto (BIOPOR) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
9 Jul, 2026Current landscape and challenges in kidney care
Acute kidney injury (AKI) and chronic kidney disease (CKD) are rising globally, now at epidemic levels, affecting up to 25% of hospitalized patients and putting one in three adults at risk for CKD, though most are unaware of their condition.
Advances in critical care have improved survival rates for children and adults with kidney issues, but many survivors now live with chronic conditions, increasing the burden on healthcare systems.
There is a severe shortage of nephrologists, especially in pediatrics, making it essential for primary care and other specialists to recognize and manage kidney disease.
Early detection using clinical phenotyping, predictive analytics, and new biomarkers is now possible and crucial for intervention.
Access to new therapies is limited by cost and insurance coverage, creating disparities in care.
Innovations and advances in diagnostics and treatment
The NGAL biomarker, developed over 25 years, enables early detection of AKI and is now FDA-cleared for pediatric use, with ongoing trials in adults.
NGAL and other biomarkers help differentiate between functional and structural kidney injury, predict dialysis needs, and are used in drug development.
AI and machine learning models are being integrated into clinical practice to predict AKI risk and optimize care, leveraging real-world data from electronic medical records and device integration.
Combining AI-generated risk scores with biomarkers aims to improve prediction accuracy and patient outcomes.
Purpose-built devices like CARPEDIEM have transformed care for neonates and infants with severe kidney disease, enabling earlier and safer dialysis.
Systemic and resource challenges
Pediatric nephrology faces a staffing crisis, with low compensation and few trainees, impacting care delivery.
Resource limitations threaten the availability of interdisciplinary teams, especially non-physician roles like dieticians and social workers, which are vital for comprehensive care.
Access to new medications is hindered by high costs and insurance barriers, particularly affecting underserved populations.
Rural and Medicaid-dependent populations are at increased risk of losing access to specialized kidney care due to funding cuts.
Latest events from BioPorto
- NGAL revenue up 33% and total revenue up 23%, with improved EBITDA loss and US adoption growth.BIOPOR
Q1 202623 May 2026 - Three-year plan targets global kidney biomarker adoption, positive cash flow by 2027, and EU expansion.BIOPOR
Status Update23 Apr 2026 - 2025 revenue up 11% year-over-year, with strong US NGAL growth and key strategic milestones.BIOPOR
Q4 202526 Mar 2026 - 2026 guidance targets 20–50% NGAL growth, expanded US adoption, and improved EBITDA loss.BIOPOR
Guidance27 Feb 2026 - NGAL diagnostics drive rapid AKI detection and global adoption, supported by strong sales and partnerships.BIOPOR
Status Update19 Jan 2026 - Q3 2025 delivered 7% revenue growth, strong US NGAL sales, and DKK 43m in new funding.BIOPOR
Q3 202519 Nov 2025 - Q2 2025 delivered strong NGAL-driven growth, a widened EBITDA loss, and a narrowed 2025 outlook.BIOPOR
Q2 202515 Aug 2025 - US NGAL sales surged 34% in 2024, fueling growth and supporting ambitious 2029 targets.BIOPOR
AGM 2025 Presentation15 Aug 2025 - 16% revenue growth driven by NGAL sales and global partnerships; 2024 guidance maintained.BIOPOR
Q3 202413 Jun 2025